



Conference on ‘Nutrition and age-related muscle loss, sarcopenia and cachexia’ Symposium 1: Sarcopenia and cachexia: scale of the problem, importance, epidemiology and measurement

Skeletal muscle mass and quality: evolution of modern measurement concepts in the context of sarcopenia

Steven B. Heymsfield^{1*}, M. Cristina Gonzalez², Jianhua Lu^{1,3}, Guang Jia^{1,3} and Jolene Zheng¹

¹Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA

²Post-Graduation Program in Health and Behavior, Catholic University of Pelotas, Pelotas, RS, Brazil

³Department of Physics and Astronomy, Louisiana State University, Baton Rouge, LA, USA

The first reports of accurate skeletal muscle mass measurement in human subjects appeared at about the same time as introduction of the sarcopenia concept in the late 1980s. Since then these methods, computed tomography and MRI, have been used to gain insights into older (i.e. anthropometry and urinary markers) and more recently developed and refined methods (ultrasound, bioimpedance analysis and dual-energy X-ray absorptiometry) of quantifying regional and total body skeletal muscle mass. The objective of this review is to describe the evolution of these methods and their continued development in the context of sarcopenia evaluation and treatment. Advances in these technologies are described with a focus on additional quantifiable measures that relate to muscle composition and ‘quality’. The integration of these collective evaluations with strength and physical performance indices is highlighted with linkages to evaluation of sarcopenia and the spectrum of related disorders such as sarcopenic obesity, cachexia and frailty. Our findings show that currently available methods and those in development are capable of non-invasively extending measures from solely ‘mass’ to quality evaluations that promise to close the gaps now recognised between skeletal muscle mass and muscle function, morbidity and mortality. As the largest tissue compartment in most adults, skeletal muscle mass and aspects of muscle composition can now be evaluated by a wide array of technologies that provide important new research and clinical opportunities aligned with the growing interest in the spectrum of conditions associated with sarcopenia.

Body composition: Nutritional assessment: Sarcopenia: Cachexia: Sarcopenic obesity

Skeletal muscle is the largest body compartment in most adults with the exception of an enlarged adipose tissue mass in the presence of obesity. The over 600 individual skeletal muscles provide a vast array of mechanical and structural functions while additionally participating in vital whole-body metabolic functions.

Skeletal muscles grow in size from birth onward, reaching peak mass in the third decade⁽¹⁾. Many factors determine an individual adult’s total body skeletal muscle mass and include their size (i.e. height)^(2,3),

magnitude of adiposity⁽⁴⁾, race^(1,5), genetic factors⁽⁶⁾, activity⁽⁵⁾, hormone⁽⁷⁾ levels and diet⁽⁸⁾. By the fourth decade populations^(1,9) and individuals⁽¹⁰⁾ begin to show a gradual loss in skeletal muscle mass and the rate of atrophy appears to accelerate beyond the seventh decade^(1,9,11). These later years are associated with sarcopenia and related functional loss of skeletal muscle, often referred to as dynapenia⁽¹²⁾, that together reflect skeletal muscle’s loss in mass, altered composition^(13,14) and lowered functionality as defined by strength and

Abbreviations: ALST, appendicular lean soft tissue; BIA, bioimpedance analysis; CT, computed tomography; DCR, deuterated creatine; DXA, dual-energy X-ray absorptiometry; HU, Hounsfield units; IMAT, intermuscular adipose tissue; SEE, standard error of the estimate.

*Corresponding author: S. B. Heymsfield, email Steven.Heymsfield@pbrc.edu




Fig. 1. The sarcopenia spectrum that includes sarcopenic obesity, frailty and cachexia that collectively have in common loss of skeletal muscle mass and functional abnormalities, including weakness and limited physical performance.

physical performance. The senescence-related changes in skeletal muscle are, in turn, associated with adverse outcomes such as pathological bone fractures and even death⁽¹⁵⁾.

Measuring skeletal muscle mass, composition, strength and physical performance is thus a vital part of not only studying sarcopenia⁽¹⁶⁾, but also of growing importance in clinically evaluating and monitoring the greatly increasing population of ageing at-risk adults in most countries. Our report highlights aspects of evaluating these features of skeletal muscle and expands on earlier methodological⁽¹⁷⁾ and historical⁽²⁾ reviews.

While the main phenotypic feature of sarcopenia is loss of lean tissue, notably skeletal muscle, there is growing recognition that sarcopenia can co-exist in the presence of obesity⁽¹⁸⁾. A skeletal muscle compartment reduced in mass may thus be masked by the presence of excess fat. Diagnosing sarcopenic-obesity may thus include measures beyond that of skeletal muscle mass such as BMI and total body fat, topics that we will allude to in the review that follows. Loss of skeletal muscle also plays an important role in two other conditions, cachexia⁽¹⁹⁾ and frailty⁽²⁰⁾, creating a spectrum of phenotypes and clinical conditions that encompass sarcopenia (Fig. 1).

Skeletal muscle evaluation

Two main factors, skeletal muscle mass and composition, are the main determinants of global muscle metabolic function, strength and physical performance. Vascular and neurological integrity are also essential components that ultimately contribute to a skeletal muscle's metabolic and mechanical functionality⁽²¹⁾. The 'quality' of a skeletal muscle is a loosely defined concept that broadly includes aspects of anatomic structure, chemical composition and metabolic and mechanical performance⁽¹³⁾. Our review encompasses aspects of measuring skeletal muscle mass, composition and function in

relation to the evaluation of individuals and groups for the presence of sarcopenia and related conditions.

Multiple methods of measuring skeletal muscle mass are available for research and clinical purposes that vary in cost, complexity and availability. The advantages and disadvantages of each method, reviewed in the following discussion, are summarised in Table 1.

Anthropometry

Searching for a measure of human working efficiency, Jindrich Matiegka reported in 1921 what was to become a classic anthropometric approach to quantifying skeletal muscle mass⁽²²⁾. Matiegka's method divided body weight into four parts: skeleton, skeletal muscle, skin plus subcutaneous adipose tissue and remainder. Crude measuring devices were used to quantify bone and extremity breadths and skinfold thickness. Estimated values were then incorporated along with the height and calculated surface area into Matiegka's body composition prediction model. Seven decades later Martin *et al.* reported in 1990 one of the first whole-body anthropometric skeletal muscle prediction models by post-mortem calibration against twelve male subjects in the Brussels Cadaver Study (Table 2)⁽²³⁾. Doupe *et al.* reported an updated version of Martin's model in 1997⁽²⁴⁾.

Others that followed Matiegka and later Martin were limited by a lack of reference standards for *in vivo* skeletal muscle mass measurement until the introduction of computed tomography (CT) by Hounsfield⁽²⁵⁾. Since then CT, MRI and dual-energy X-ray absorptiometry (DXA) have all been used as the reference for developing anthropometric skeletal muscle mass prediction equations. Expanding on the Brussels Cadaver Study strategy, Lee *et al.*⁽¹⁷⁾ reported anthropometric skeletal muscle mass prediction equations developed in 244 adults using MRI as the reference (Table 2).

The most recent anthropometric approach was reported in 2014 by Al-Gindan *et al.*⁽²⁶⁾ using total body skeletal muscle mass collected on 423 adults varying in age, sex, race and BMI using whole-body MRI as the reference. An additional 197 subjects served as a validation sample. The author's main aim was to develop equations that incorporated commonly used measures that typically are collected in large population studies and surveys. The Al-Gindan prediction equations are summarised for men (derivation: R^2 0.76, standard error of the estimate (SEE) 2.7 kg; validation: R^2 0.79, SEE 2.7 kg) and women (derivation: R^2 0.58, SEE 2.2 kg; validation: R^2 0.59, SEE 2.1 kg) in Table 2.

Simple regional skeletal muscle estimation approaches are also available that are practical to apply in the clinical setting. For example, appendicular cross-sectional muscle plus bone areas can be derived using a combination of skinfold and circumference measurements (Table 2)^(27,28). Similar equations are also available that correct for bone inclusion within the skeletal muscle compartment⁽²⁸⁾.

While anthropometry as a means of estimating skeletal muscle mass has several important advantages, use in the elderly poses problems not encountered in younger adults

Table 1. Advantages and disadvantages of skeletal muscle mass measurement methods

Method	Measurements	Advantages	Disadvantages
Anthropometry	Skinfold thicknesses, circumferences and linear dimensions	Non-invasive and inexpensive Applicable in large surveys	Training required. Poor precision in obese subjects. Skinfold compressibility changes with age due to a loss in skin elastic recoil and increase in viscoelastic recovery time; skinfolds in the elderly are often pendulous and difficult to measure due to loss of underlying muscle tone; pendulous skinfolds may also make circumferences more difficult to measure; bony landmarks are more difficult to identify in the obese. The SM compartment includes intramuscular adipose tissue, a component that increases with age and that is included within the anthropometric skeletal muscle estimate
Urinary metabolites	24-h creatinine and 3-methyl histidine	Non-invasive, safe, relatively inexpensive. Reflects muscle cell mass	Requires subject cooperation, ideally collecting several consecutive 24 h urine samples while ingesting a meat-free diet
Ultrasound	Muscle width and area	Non-invasive, safe, widely available, useful for longitudinal monitoring	Technical skill required. Excess transducer pressure and orientation can influence muscle size measurements. Identification of reproducible measurement sites critical. Care needed to make muscle is in relaxed state. Conditions such as proximity to exercise bout, hydration, etc. are important to control
Bioimpedance Analysis	Segmental impedance, resistance and reactance; phase angle	Variable instrument cost, safe, potentially portable, useful for long-term monitoring and longitudinal studies	Measurements sensitive to subject conditions such as hydration and recent activity. Instrument predictions may be population specific
<i>Imaging</i>			
CT	Cross-sectional muscle area, muscle attenuation	High resolution; three-dimensional reconstruction; regional/whole-body; CT# SM quality measure	Radiation exposure, cost, subject size limitations
DXA	Lean soft tissue, fat and bone mineral content; other measures of bone quality	Wide availability; high precision; low radiation; regional and whole-body measurements of the three components	Modest cost, size (weight and height) limitations. Cannot specifically discern skeletal muscle mass and quality as can CT and MRI
MRI	Cross-sectional muscle area	High resolution; three-dimensional reconstruction; multiple measures of SM quality (Table 3)	Relatively high cost, subject size limitations

SM, skeletal muscle; CT, computed tomography; CT#, linear attenuation coefficient; DXA, dual-energy X-ray absorptiometry.
Modified from references^(17,27,99).

and children. These strengths and limitations of anthropometry are summarised in Table 1. Notably, anthropometric measurements are unable to discern the active contractile components from adipose and connective tissues embedded within the muscle compartment. These components may impact functional measures and account for the often-observed dissociation that occurs over time with ageing between skeletal muscle mass and function^(29,30).

Urinary markers

Discovered in meat by Chevreul in 1835, creatine is a metabolite distributed primarily in skeletal muscle and to a lesser extent in brain and other tissues⁽³¹⁾. Creatine undergoes non-enzymatic degradation to creatinine at a stable rate and this metabolic end-product is then excreted unchanged in urine. Urine collected over 24 h

from subjects ingesting a meat-free diet can be analysed for creatinine and early workers assumed levels are directly proportional to skeletal muscle mass (1 g = about 20 kg)⁽³²⁾. Forbes and Bruining in 1976 developed a urinary creatinine prediction equation with total body potassium-measured 'lean body mass' as the reference for skeletal muscle (Table 2)⁽³³⁾.

With the introduction of CT in the 1970s it became possible for the first time to accurately quantify the total body skeletal muscle mass in living subjects. Wang *et al.* in 1996 used CT to quantify the relation between 24 h urinary creatinine and skeletal muscle mass in twelve healthy men (Table 2, R 0.92, SEE 1.89 kg; P < 0.001)⁽³⁴⁾. More recently, Clark and Manini⁽³⁵⁾ used MRI to measure skeletal muscle mass in subjects ingesting a gel capsule filled with deuterated creatine (DCR). The stable isotope DCR provides a means of measuring the subject's total body creatine pool size with mass

Table 2. Some method-specific equations used to estimate regional and total skeletal muscle mass

Method	Equation	Reference
Anthropometry	$SM = Ht \text{ (cm)} \times (0.0553 \times CTG^2 + 0.0987 \times FG^2 + 0.0331 \times CCG^2) - 2445$	(23)
	$SM = Ht \times (0.031 \times MUTHG^2 + 0.064 \times CCG^2 + 0.089 \times CAG^2) - 3006$	(24)
	$SM = Ht \text{ (m)} \times (0.0074 \times CAG^2 + 0.00088 \times CTG^2 + 0.00441 \times CCG^2) + 2.4 \times \text{sex} - 0.048 \times \text{age} + \text{race} + 7.8$	(17)
	Race: Asian, -2.0; African American, 1.1; Caucasian or Hispanic, 0.	(17)
	$SM = 0.244 \times BW + 7.80 \times Ht \text{ (m)} - 6.6 \times \text{age} + 0.098 \times \text{sex} + \text{race} - 3.3$	(17)
	Race: Asian, -1.2; African American, 1.4; Caucasian or Hispanic, 0.	(17)
	$SM = 39.5 + 0.665 \times BW - 0.185 \times WC - 0.418 \times HC - 0.08 \times \text{age (men)}$	(26)
	$SM = 2.89 + 0.255 \times BW - 0.175 \times HC - 0.038 \times \text{age} + 0.118 \times Ht \text{ (cm) (women)}$	(26)
	$\text{Calf muscle area (cm}^2\text{)} = \frac{[MCC - \pi \times CSF]^2}{4\pi}$	(26)
	$\text{Thigh muscle area (cm}^2\text{)} = \frac{[MTC - \pi \times THSF]^2}{4\pi}$	(27)
	$\text{Arm muscle area (cm}^2\text{)} = \frac{[MAC - \pi \times TSF]^2}{4\pi}$	(27)
Urinary metabolites	$SM = 18.9 \times Cr + 4.1$	(34)
	$SM = 0.118 \times 3\text{-MH} - 3.45$	(37)
	$SM = 0.0887 \times 3\text{-MH} + 11.8$	(100)
Ultrasound	$SM = 0.641 \times MT \times Ht \text{ (m)} - 12.087 \text{ (Men)}$	(44)
	$SM = 0.594 \times MT \times Ht \text{ (m)} - 11.320 \text{ (Women)}$	(44)
BIA	$SM = 0.401 \times Ht \text{ (cm)}^2 / R + 3.825 \times \text{sex} - 0.071 \times \text{age} + 5.102$	(101)
DXA	$ASM = ALST - \text{appendicular BMC} \times 1.82$	(17, 78)
	$SM = ASM \times 1.33$	(17, 78)
	$SM = 1.19 \times ALST - 1.01$	(79)
	$SM = 1.13 \times ALST - 0.02 \times \text{age} + 0.61 \times \text{sex} + 0.97$	(79)
Abbreviations and units	3-MH, 3-methylhistidine (mmol/d); age (years); ALST, appendicular lean soft tissue (kg); ASM, appendicular skeletal muscle (kg); BMC, bone mineral content (kg); BW, body weight (kg); CAG, corrected arm girth (cm); CCG, corrected calf girth (cm); CSF, calf skinfold (cm); Cr, 24 h urinary creatinine (g/d); CTG, corrected thigh girth (cm); FG, uncorrected forearm girth (cm); HC, hip circumference (cm); Ht, height (units, see the specific model); MAC, mid-arm circumference (cm); MCC, mid-calf circumference (cm); R, resistance (Ω); MT, muscle thickness (cm) summed for nine measurement sites; THSF, thigh skinfold (cm); MTC, mid-thigh circumference (cm); MUTHG, modified upper thigh girth (cm); sex, one male, zero female; SM, skeletal muscle (kg); TSF, triceps skinfold (cm); WC, waist circumference (cm)	

BIA, bioimpedance analysis; DXA, dual-energy X-ray absorptiometry.

spectroscopy used to analyse urine samples collected over several days. Skeletal muscle mass measured by DCR was well correlated with skeletal muscle mass measured with MRI as the reference ($R\ 0.868$, $P < 0.001$)⁽³⁵⁾. A recent study by Patel *et al.*⁽³⁶⁾ advanced the concept that serum creatinine can serve as a biomarker of skeletal muscle mass assuming adjustments are made for renal function and dietary meat intake.

Urinary Ntau-methylhistidine (3-methylhistidine) has also been used to estimate skeletal muscle mass⁽³⁷⁾. Skeletal muscle contractile proteins, actin and myosin, are methylated after completion of peptide bond synthesis leading to the production of 3-methylhistidine. The 3-methylhistidine is released with protein catabolism and excreted unchanged in the urine. While urinary 3-methylhistidine collected over 24 h is typically used to evaluate the rate of myofibrillar protein breakdown, empirical skeletal muscle mass prediction equations have also been published (Table 2). Because of 3-methylhistidine's complex metabolism, analytical costs and introduction of other competing methods, few workers today continue to use this metabolic end-product as a means of estimating skeletal muscle mass.

A limitation of urinary creatinine and 3-methylhistidine as markers of skeletal muscle mass is the requirement for dietary control and multiple 24-h urine collections that are applied together for optimum results. In the absence of other available methods, however, the cost of these approaches is minimal and there are no subject safety concerns as with some imaging methods. Additional research is needed on the use of DCR and serum creatinine for quantifying skeletal muscle mass.

Separate from measurement concerns, the two urinary markers conceptually reflect muscle cell mass rather than whole muscle that also includes embedded adipose tissue, connective tissues and extracellular fluid. Anthropometry, which measures whole muscle, may therefore give differing impressions of age-related changes than a marker such as urinary creatinine or DCR that capture muscle cell mass.

Ultrasound

Recent technological advances provide new opportunities for application of ultrasound in evaluating skeletal

Table 3. Magnetic resonance measurements and approaches for evaluating skeletal muscle that go beyond conventional volumetric rendering

Measurement	Comment	Reference
IMAT	Measured on conventional CT scan and T1-weighted images. IMAT linked with metabolic and clinical outcomes; IMAT-free SM proportionally decreased in the elderly	(74)
Short- τ inversion recovery	Muscle oedema characterised by increased SM signal intensity	(102)
UTE	Visualisation of cortical bone, tendons, and ligaments. UTE imaging helps define mechanically-active portions of SM. Connective-tissue free SM decreased in the elderly	(103)
Magnetic resonance elastography	Evaluates SM viscoelastic properties/stiffness that may be adversely influenced by the presence of sarcopenia	(104)
Diffusion weighted imaging	Apparent diffusion coefficient gives a measure of muscle cell membrane integrity and perfusion through the microcirculation	(2, 102)
DTI	DTI measures anisotropy of water diffusion giving a measure of muscle cellular orientation and integrity. Measures such as fractional anisotropy give estimates of muscle microstructure	(102)
MRS	¹ H MRS provides intracellular component measures such as IMCL. ³¹ P MRS provides information on high-energy intermediates and related metabolic processes.	(84, 105) (106)
CEST	¹³ C MRS gives information on SM triacylglycerol, glycogen and insulin resistance CEST tracks exchange of protons in amine ($-NH_2$) to bulk water. Visualisation of dynamic changes in free creatine in exercised muscle	(107)

IMAT, intermuscular adipose tissue; CT, computed tomography; UTE, ultra-short echo-time imaging; IMCL, intramyocellular lipid; SM, skeletal muscle; DTI, diffusion tensor imaging; MRS, magnetic resonance spectroscopy; CEST, chemical exchange saturation transfer.

muscle mass and quality. Karl Dussik at the University of Vienna was the first to apply ultrasound methods in 1942 with early attempts at diagnosing brain tumours⁽³⁸⁾. Eight years later, George Ludwig at the United States Naval Research Institute further improved ultrasound methods for diagnosing the presence of gallstones⁽³⁹⁾. A piezoelectric crystal housed in the transducer probe produced high-frequency sound waves. The directed sound waves passed through the skin surface and then reflected off underlying anatomic structures, including skeletal muscle and bone interfaces. Returning sound waves, or echoes, were then captured by a receiver housed in the transducer probe. The same fundamental technology is in use today.

A-mode ultrasound emerged in the 1960s as an alternative to skinfold calipers in evaluating subcutaneous adipose tissue layer thickness⁽⁴⁰⁾. A-mode systems provide an amplitude-modulated display that represents the intensity of returning echoes. This allows visualisation of various tissue interfaces and thereby measurement of fat and muscle ‘thickness’ at pre-defined anatomic sites. Commercial A-mode systems are in use today for measuring adipose tissue and skeletal muscle thickness at pre-defined anatomic sites⁽⁴¹⁾. More recently B-mode systems provide a brightness-modulated display for echoes returning to the system transducer. B-mode systems display two-dimensional cross-sectional images of adipose tissue, skeletal muscle and bone structures. Newer ultrasound systems provide three-dimensional skeletal muscle images and thus selected total muscle volumes⁽⁴²⁾.

Two investigators at the University of Tokyo, Ikai and Fukunaga, were among the first to use ultrasound for measuring skeletal muscle cross-sectional areas in 1968⁽⁴³⁾. Sanada *et al.*⁽⁴⁴⁾ measured skeletal muscle thickness in Japanese adults with ultrasound at several anatomic sites and the authors reported total body prediction equations using MRI as the reference. Abe *et al.*⁽⁴⁵⁾ recently reviewed previously published regional and total muscle mass ultrasound prediction equations

using DXA as the reference criterion. The authors observed good correlations between DXA-derived muscle indices and corresponding ultrasound predictions (R all ≥ 0.9 and $P < 0.001$) in men and women with variable between-method significant bias, Sanada’s total muscle mass equation (Sanada *et al.*⁽⁴⁴⁾) being the only one without non-significant bias. In another recent report, Loenneke *et al.*⁽⁴⁶⁾ suggested that skeletal muscle thickness measured at the anterior portion of the thigh can be used to track age-related changes in muscle size.

Ultrasound is increasingly being used to provide estimates of skeletal muscle quality. Ultrasound elastography, is a real-time method of visualising the distribution of skeletal muscle tissue strain and elastic modulus⁽⁴⁷⁾. Several ultrasound elastography methods are available that differ in the way tissue stress is applied and the method used to detect and reconstruct the displaced tissue image⁽⁴⁷⁾. The most common of these is strain ultrasound elastography in which one approach is to manually apply low-frequency tissue compression with the transducer probe. The resulting axial muscle tissue displacement (i.e. strain) can then be detected and quantified. Ageing and sarcopenia through associated changes in skeletal muscle quality (e.g. fibrosis) may result in biomechanical alterations (stiffness and loss of elasticity) that are detectable by ultrasound elastography.

Healthy muscle is echolucent or ‘dark’ as sound waves pass through the homogenous tissue and are reflected back only when they interact with fibrous structures such as vasculature and epimysium⁽⁴⁸⁾. As subjects age and develop sarcopenia skeletal muscles increasingly have adipose tissue infiltration and fibrosis that lead to new sound reflection planes⁽⁴⁹⁾. These changes are accompanied by an increase in echogenicity, indicated as whiter muscles in ultrasonography, and the amount of ‘white’ and ‘dark’ muscle tissue of the sonographic images can be quantified by the degree of the echolucencies in human subjects^(40,50). These effects are readily

evaluated using ultrasound imaging software. As a representative example, Watanabe *et al.*⁽⁵⁰⁾ recently observed an inverse association between echo intensity and muscle strength in elderly men.

Bioimpedance analysis

Bioimpedance analysis (BIA) was pioneered in the 1950s and 1960s by Hoffer, Nyboer and Thomasset^(51–53). Today BIA is widely used in the study of human body composition as instruments are available, relatively inexpensive and analyses require minimal technician participation even when using research-grade systems. When a weak alternating current is applied across a limb the net conductivity reflects features of the traversed tissues⁽⁵¹⁾. Fluid and electrolyte-rich soft tissues, particularly skeletal muscle, are highly conductive by comparison with low-hydration tissues such as bone. All BIA systems exploit these tissue-specific conductivity differences to quantify body compartments such as skeletal muscle and adipose tissue.

Many system designs are available that range from single to multiple frequency, employ contact or gel-electrodes and that measure segmental or whole-body electrical pathways. All BIA systems measure impedance and/or its two components, resistance and reactance. These electrical measurements in turn can be incorporated into body composition prediction models that have empirical and/or theoretical underpinnings.

The most important advance in relation to skeletal muscle was reported by Organ *et al.*⁽⁵⁴⁾. Organ *et al.* first described a six-electrode method for segmental BIA that allowed isolation of separate electrical properties of each extremity and the trunk. Several years later Tan *et al.*⁽⁵⁵⁾ described construction of an eight-electrode BIA stand that included contact electrodes for the upright subject's feet and hands. The impedance measures of the arm and leg could then be empirically calibrated to either DXA appendicular lean soft tissue mass (ALST), mainly skeletal muscle or MRI-derived skeletal muscle mass.

Brown *et al.*⁽⁵⁶⁾ were the first to use BIA for estimating upper arm cross-sectional muscle and fat areas using CT as the reference. By 2000 Janssen *et al.*⁽⁹⁾ reported a whole-body skeletal muscle mass BIA prediction equation using MRI as the calibration method (Table 2). Today several commercially available BIA systems report appendicular and even whole-body skeletal muscle mass with DXA as the usual reference for extremity estimates. We recently reported good correlations between BIA-derived (MC-980, Tanita Corp., Tokyo, Japan) appendicular skeletal muscle mass and corresponding DXA (iDXA, GE Lunar, Madison, WI, USA) lean soft tissue estimates (R^2 0.92, $P < 0.001$) in 130 children and adults⁽⁵⁷⁾. Most commercial BIA systems rely on proprietary prediction equations for total and regional fat and skeletal muscle mass.

In addition to skeletal muscle estimates, BIA also can provide measures of muscle quality and function. Phase angle can be assessed directly from the relationship between the measured resistance (R) and reactance (X_c) values (Phase angle ($^\circ$) = $\arctangent(X_c/R) \times (180/\pi)$). Phase angle not only provides useful body composition

information, but also reflects cell membrane function and it has clinical prognostic value⁽⁵⁸⁾. Although the underlying biological mechanisms of phase angle are not well defined, a recent study⁽⁵⁸⁾ suggests that age is a main determinant after controlling for other covariates. Data from several large-scale studies across different countries and race/ethnic groups show a consistent pattern with peak phase angle values during early adulthood and then values gradually decline in later years independent of body composition⁽⁵⁸⁾. The basis of this age-related decline in phase angle is not well understood but parallel changes are observed in skeletal muscle ultrasound echogenicity⁽⁵⁹⁾, a finding suggesting that chemical and anatomic changes in muscle may account in part for the observed effects. In a recent study, Basile *et al.*⁽⁶⁰⁾ reported independent effects of grip strength and skeletal muscle mass on phase angle measured in a cohort of elderly adults; low phase angle was associated with reduced grip strength. Slee *et al.*⁽⁶¹⁾ evaluated a cohort of frail older hospitalised patients, some of whom were malnourished, and observed a low phase angle compared with healthy elderly reference values⁽⁶¹⁾. Age-related changes in other BIA resistance and reactance ratios and combinations at different frequencies are also recognised. Taken together these findings suggest that BIA may provide information on skeletal muscle quality that may ultimately yield prognostic information.

Body weight scales that incorporate BIA technology through contact foot electrodes can also be modified to provide functional and balance information⁽⁶²⁾. The scale platform force transducers can capture the subject's generated power and stability as they stand erect from a stable crouched or seating position. With appropriate protocols these kinds of instruments, now in development, can potentially yield information on skeletal muscle mass, composition (e.g. phase angle or other age-related BIA measure) and functionality.

The strengths and limitations of BIA are summarised in Table 1. Since so many systems differing in design are available, generalisations on accuracy and overall quality are not possible in the context of this review. The features and supporting literature for each instrument should be scrutinised by the interested investigator or clinician. Of importance for all BIA systems is the presence of stable subject conditions at the time of measurement. Hydration, time of day and many other factors influence measured subject impedance values and meticulous adherence to manufacturer-specified conditions will ensure optimum results.

Imaging

The discovery of X-rays by Röntgen in 1895 transformed not only clinical medicine, but the field of body composition research as a whole. By 1942 Harold C. Stuart and P. Hill-Dwinell at Harvard evaluated muscle and fat 'widths' in growing children⁽⁶³⁾. Godfrey Hounsfield at EMI in London revolutionised biomedical imaging with the introduction of the first functional CT scanner in 1975⁽⁶⁴⁾ and not long after three publications on CT-measured skeletal muscle appeared between

1978 and 1979^(65–67). CT provided the first accurate approach for quantifying whole-body muscle mass in living human subjects in the mid-1980s^(68,69).

Following up on a long series of important discoveries in physics, Raymond Damadian at SUNY Downstate introduced the first human MRI scanner in 1977⁽⁷⁰⁾. Studies of skeletal muscle biology proliferated in the 1980s as MRI system availability increased and investigators were able to scan subjects of all ages without the radiation concerns associated with CT. Working with a skeletal orientation related to osteoporosis, Mazess *et al.* first introduced the dual-photon absorptiometry concept in 1970 for bone evaluation in the presence of overlying soft tissues⁽⁷¹⁾. Modern DXA systems that can also provide body composition estimates, including measures of skeletal muscle mass, were introduced in the late 1980s⁽⁷²⁾. Thus, within several decades the body composition field went from relying on such limited skeletal muscle mass estimation methods as anthropometry and urinary creatinine excretion to advanced imaging methods such as CT, MRI and DXA. So far, ten Nobel Prizes have been awarded for development of imaging technology (Supplementary Table S1) that has had a major impact on sarcopenia research and clinical practice.

Computed tomography

CT was the first method introduced that could quantify whole-body and regional skeletal muscle mass with high accuracy. High-resolution cross-sectional images of pre-defined slice width can be analysed for each tissue, including skeletal muscle, using hand segmentation or automated software. Depending on the study, varying numbers of cross-sectional images can be combined to evaluate single muscle areas, volumes or whole-body skeletal muscle mass.

Each image picture element, or pixel, is defined by a linear attenuation coefficient or CT# reported in Hounsfield units (HU). Water is internationally defined as 0 HU and air as –1000 HU. Adipose tissue has negative HU values, whereas skeletal muscle has positive HU values and these tissue X-ray attenuation differences can be exploited for analytical purposes during hand segmentation or by automated software.

The segmented CT scan provides measures of skeletal muscle area and multiple images at specified intervals can be used to derive regional or total volumes. Most investigators then calculate skeletal muscle mass from the measured volume as the product of volume and density, usually assumed as 1.04 g/cm³⁽¹¹⁾.

With ageing, disuse or in pathological states increasing amounts of adipose tissue can be found within skeletal muscles, particularly of the lower extremities⁽⁷³⁾. This intermuscular adipose tissue (IMAT) can be quantified during the analysis and the analyst can then report the values for IMAT and IMAT-free skeletal muscle⁽⁷⁴⁾. At the molecular level, skeletal muscle is composed of proteins, water, electrolytes, lipids and small amounts of other compounds. Each of these molecular species has a known physical density and closely related attenuation and HU in the context of CT. Iron or fat infiltration of the liver raises and lowers hepatic HU values,

respectively⁽⁷⁵⁾. These tissue attenuation effects can be exploited to quantify pathological changes within liver and other tissues. Similarly, a low tissue HU may be a marker of lipid or fluid infiltration in skeletal muscles that can be accompanied by functional changes⁽⁷⁶⁾. CT can thus provide through evaluated HU values a measure of skeletal muscle quality.

An advantage of CT is high-quality image reconstruction and stable attenuation values that aid in image segmentation and also provide a measure of tissue composition and quality. The radiation exposure of CT and relatively high-cost limit current applications mainly to research or in clinical settings that include CT scanning as part of routine patient care⁽⁷⁷⁾.

Differential absorptiometry

The availability of DXA systems, modest scan cost, low radiation exposure, short scan time and extensive information provided from each scan makes this approach the most widely used in sarcopenia research and clinical practice at the current time. The DXA approach provides estimates of three body compartments, lean soft tissue, bone mineral content and fat for the whole body and at least four regions, head, trunk, arms and legs. DXA also gives additional skeletal information of value in managing osteoporosis and other clinical conditions related to bone biology.

The lean soft tissue found in the arms and legs, referred to as ALST, has a high muscle content that constitutes a large fraction of total body skeletal muscle mass⁽⁷⁸⁾. Measured ALST can thus be used as a surrogate measure of skeletal muscle mass and can be calibrated against whole-body values derived by CT or MRI⁽⁷⁹⁾. The calibration process provides various prediction equations that can be used to derive total body skeletal muscle mass from the measured ALST value (Table 2).

Since DXA provides measures of regional and total body fat and bone, these components can also be used to evaluate the composite musculoskeletal system (i.e. muscle plus bone) and the level of adiposity. The pathological outcomes associated with sarcopenia often derive from combinations of the amount and quality of skeletal muscle, bone and fat present^(80,81).

Magnetic resonance

The introduction of MRI in the 1980s expanded the initial use of CT as means of developing three-dimensional images of skeletal muscle, adipose tissue and other organs. This development is usually referred to as structural or anatomic imaging. The lack of subject exposure to ionising radiation positions MRI as the method of choice for quantifying skeletal muscle across the full lifespan. Most modern MRI scanners can accommodate obese subjects, particularly with the newer wide bore (70 cm) systems.

Water-fat imaging

As with CT, the traditional analysis approach is hand- or partially automated image segmentation. The hand-

segmentation approach to the whole-body MRI analysis is tedious, time-consuming and costly. Recent advances in water–fat imaging may soon allow automation of the segmentation process. Relaxation times and resonance frequencies are different for water and fat protons in their respective environments and these differences can be used to suppress the fat-bound signal⁽⁸²⁾. Two imaging approaches are available for exploiting these differences, relaxation-dependent or short inversion-time recovery and chemical shift-dependent or Dixon-based fat suppression⁽⁸²⁾. Karlsson *et al.* recently reported development of a two-point Dixon sequence automated water–fat segmentation method for evaluating total body and regional skeletal muscle volume⁽⁸³⁾. The authors showed excellent test–retest reliability (intraclass correlation coefficient 1.0, 95 % agreement level –0.32 to 0.2 litres) and agreement with hand-segmented images of the lower leg (correlation *R* values 0.94–0.96) in a follow-up study using a 3T wide-bore MRI scanner and integrated quadrature body coil⁽⁸⁴⁾. Scan times were about 10 min and the results were evaluated for total body and eight regional skeletal muscle volumes. Shortening the whole-body analysis time is an important advance that could provide an opportunity for evaluating large and diverse samples for prediction model development expanding on the examples presented in Table 2.

In addition to total body and regional skeletal muscle mass, other features of skeletal muscle quality can also be evaluated with MRI and CT such as IMAT⁽⁷⁴⁾. Skeletal muscle in persons with sarcopenia is characterised by an enlarged IMAT component, notably in the lower extremities^(73,74). Water–fat imaging has also been used to evaluate regional skeletal muscle fat infiltration, and as noted earlier, the CT# gives an indication of water and fat infiltration into skeletal muscles⁽⁷⁶⁾.

An important advance in the context of sarcopenia is a wide array of new magnetic resonance sequences and technology that have the potential to give new structural and functional information about individual muscles and whole-body skeletal muscle mass. These approaches are summarised in Table 3.

Integration with sarcopenia

Adjusting measurements for body size

The adult skeletal muscle compartment increases in size as a function of subject stature and adiposity. Quetelet in 1842 first showed that among adults body weight (*W*) increases as height (*Ht*) squared ($W \propto Ht^2$)⁽⁸⁵⁾. For most populations W/Ht^2 is independent of height and this observation forms a main basis of BMI⁽³⁾. Van Itallie *et al.* in 1990 suggested that BMI be further divided into two height-normalised indices, fat mass index (FM/Ht^2) and fat-free mass index (FFM/Ht^2)⁽⁸⁶⁾. Support for this suggestion came later when Heymsfield *et al.* showed that adult fat-free mass also scales to height with powers of approximately 2⁽³⁾, thus making fat-free mass index independent of height. Baumgartner *et al.* working with ALST measured with dual-photon absorptiometry, extended Van Itallie's concept by deriving

ALST/ Ht^2 as a sarcopenia index⁽⁸⁷⁾. Although it now appears as if adult skeletal muscle scales to height with powers slightly greater than 2⁽⁸⁸⁾, indices such as Baumgartner's would likely only show weak correlations with height.

The growing interest in sarcopenia has led others to suggest additional indices. One explored in the recent Foundation for the National Institutes of Health sarcopenia guidelines is appendicular lean mass (i.e. ALST)/BMI. Other approaches, also based on DXA measurements, are more functional in design such as Siervo's load-capacity model in which one calculated measure is trunk fat (load) divided by lower leg lean soft tissue (capacity)⁽⁸⁹⁾.

As with greater stature, increasing adiposity also leads to larger amounts of skeletal muscle mass. Forbes⁽⁹⁰⁾ and more recently Thomas *et al.*⁽⁴⁾ developed quantitative models linking fat-free mass index (i.e. a proxy for muscle) and fat mass index. Thus, 'cut-points' for muscle indices need to consider subject adiposity when evaluating conditions such as sarcopenic obesity.

Mass v. function

Throughout our review we have endeavoured to identify methods that not only provide skeletal muscle mass estimates, but to go beyond by describing how these methods also reveal new information on muscle composition or quality. A vast literature now shows how skeletal muscle mass, function and outcomes are often uncoupled as people age. Moreover, in some cases body compartments such as fat mass are even stronger predictors of outcome measures in elderly subjects than skeletal muscle mass⁽⁹¹⁾. These efforts are further clarifying the sarcopenia spectrum and the examination of the many reviewed muscle quality measures will likely improve our understanding of underlying mechanisms and, additionally, provide new clinically useful biomarkers of senescence-related changes in skeletal muscle.

Guideline development

Evaluating subjects for the presence of sarcopenia involves quantifying strength and physical performance. We briefly mention these aspects of muscle evaluation in the context of the present review. Additional details can be found in the reviews of Cooper *et al.*⁽⁹²⁾ and Guralnik⁽⁹³⁾.

Strength evaluations typically focus on isolated muscle groups and include commonly used tests such as handgrip strength, knee flexion/extension, peak expiratory flow rate and maximum force/isotonic–isokinetic/arms–legs. Measures of performance collectively capture strength, coordination, aerobic fitness and balance. These tests typically include the Short Physical Performance Battery, usual gait speed, timed get-up-and-go test, stair climb power test and timed walk test⁽⁹⁴⁾.

Often tests of skeletal muscle strength and physical performance will show relatively larger reductions over time in monitored elderly subjects and, importantly, demonstrate stronger associations with sarcopenia outcomes such as weakness, falls and fractures. While the

first phenotypic expression of sarcopenia by Rosenberg in 1988 was loss of ‘flesh’ or muscle mass⁽⁹⁵⁾, guidelines are increasingly focusing on functional measures as the first step in subject evaluations. The European Working Group of the Study of Older People (age >65 years) included a stepped algorithm with measures of performance (gait speed) and strength (grip) proceeding a measure of skeletal muscle mass⁽⁸⁰⁾ leading to the diagnosis of sarcopenia. More recently, the Foundation for the National Institutes Health recommended a screening algorithm designed for subjects presenting with poor physical function that starts with quantifying weakness (grip strength) followed by evaluation of muscle mass adequacy (DXA appendicular lean mass adjusted for BMI)^(16,96–98).

Further refinements in sarcopenia guidelines are likely as measurement methods improve, additional outcome studies are conducted and other conditions such as sarcopenic obesity, cachexia and frailty are subject to similar critical algorithm development.

Conclusions

Methods of quantifying skeletal muscle mass continue to evolve providing a vast array of choices for use in research and clinical settings. The gap present between findings based on ‘mass’ and ‘functional’ measures likely can be closed in part with new approaches for evaluating skeletal muscle composition and quality. These translational approaches have the potential for identifying those at risk for developing sarcopenia and related disorders at an early stage during which interventions may be most effective in preventing morbidity and mortality.

Supplementary material

To view supplementary material for this article, please visit <http://dx.doi.org/10.1017/S0029665115000129>.

Acknowledgements

The authors acknowledge the support of Ms Robin Post in manuscript preparation and Dr Neil Johannsen for his guidance on indicators of skeletal muscle strength and performance.

Financial Support

There was no external support for development of this manuscript.

Conflicts of Interest

S. B. H. is on the Medical Advisory Board of Tanita Corp., Tokyo, Japan. The company develops and manufactures bioimpedance analysis systems.

Authorship

S. B. H. drafted the manuscript outline and coordinated individual sections prepared by M. C. G., J. L., G. J. and J. Z. All the authors contributed to review and editing of the final report.

References

1. Silva AM, Shen W, Heo M *et al.* (2010) Ethnicity-related skeletal muscle differences across the lifespan. *Am J Hum Biol* **22**, 76–82.
2. Heymsfield SB, Adamek M, Gonzalez MC *et al.* (2014) Assessing skeletal muscle mass: historical overview and state of the art. *J Cachexia Sarcopenia Muscle* **5**, 9–18.
3. Heymsfield SB, Peterson CM, Thomas DM *et al.* (2014) Scaling of adult body weight to height across sex and race/ethnic groups: relevance to BMI. *Am J Clin Nutr* **100**, 1455–1461.
4. Thomas D, Das SK, Levine JA *et al.* (2010) New fat free mass – fat mass model for use in physiological energy balance equations. *Nutr Metab (Lond)* **7**, 39.
5. Heymsfield SB, Scherzer R, Pietrobelli A *et al.* (2009) Body mass index as a phenotypic expression of adiposity: quantitative contribution of muscularity in a population-based sample. *Int J Obes (Lond)* **33**, 1363–1373.
6. McNally EM (2004) Powerful genes – myostatin regulation of human muscle mass. *N Engl J Med* **350**, 2642–2644.
7. Bhasin S, Cunningham GR, Hayes FJ *et al.* (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* **95**, 2536–2559.
8. Houston DK, Nicklas BJ, Ding J *et al.* (2008) Dietary protein intake is associated with lean mass change in older, community-dwelling adults: the Health, Aging, and Body Composition (Health ABC) Study. *Am J Clin Nutr* **87**, 150–155.
9. Janssen I, Heymsfield SB, Wang ZM *et al.* (2000) Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr. *J Appl Physiol* **89**, 81–88.
10. Forbes GB (1999) Longitudinal changes in adult fat-free mass: influence of body weight. *Am J Clin Nutr* **70**, 1025–1031.
11. Gallagher D, Ruts E, Visser M *et al.* (2000) Weight stability masks sarcopenia in elderly men and women. *Am J Physiol Endocrinol Metab* **279**, E366–E375.
12. Alexandre Tda S, Duarte YA, Santos JL *et al.* (2014) Sarcopenia according to the European Working Group on Sarcopenia in Older People (EWGSOP) versus dynapenia as a risk factor for mortality in the elderly. *J Nutr Health Aging* **18**, 751–756.
13. McGregor RA, Cameron-Smith D & Poppitt SD (2014) It is not just muscle mass: a review of muscle quality, composition and metabolism during ageing as determinants of muscle function and mobility in later life. *Longev Healthspan* **3**, 9.
14. Yamada Y, Schoeller DA, Nakamura E *et al.* (2010) Extracellular water may mask actual muscle atrophy during aging. *J Gerontol A Biol Sci Med Sci* **65**, 510–516.
15. Filippin LI, Teixeira VN, da Silva MP *et al.* (2014) Sarcopenia: a predictor of mortality and the need for early diagnosis and intervention. *Aging Clin Exp Res* (Epublication ahead of print version).
16. Studenski SA, Peters KW, Alley DE *et al.* (2014) The FNIH sarcopenia project: rationale, study description,

- conference recommendations, and final estimates. *J Gerontol A Biol Sci Med Sci* **69**, 547–558.
17. Lee RC, Wang ZM & Heymsfield SB (2001) Skeletal muscle mass and aging: regional and whole-body measurement methods. *Can J Appl Physiol* **26**, 102–122.
 18. Kob R, Bollheimer LC, Bertsch T *et al.* (2015) Sarcopenic obesity: molecular clues to a better understanding of its pathogenesis? *Biogerontology* **16**, 15–29.
 19. Johns N, Hatakeyama S, Stephens NA *et al.* (2014) Clinical classification of cancer cachexia: phenotypic correlates in human skeletal muscle. *PLoS ONE* **9**, e83618.
 20. Milte R & Crotty M (2014) Musculoskeletal health, frailty and functional decline. *Best Pract Res Clin Rheumatol* **28**, 395–410.
 21. Walston JD (2012) Sarcopenia in older adults. *Curr Opin Rheumatol* **24**, 623–627.
 22. Matiegka J (1921) The testing of physical efficiency. *Am J Phys Anthropol* **4**, 223–230.
 23. Martin AD, Spenst LF, Drinkwater DT *et al.* (1990) Anthropometric estimation of muscle mass in men. *Med Sci Sports Exerc* **22**, 729–733.
 24. Doupe MB, Martin AD, Searle MS *et al.* (1997) A new formula for population-based estimation of whole body muscle mass in males. *Can J Appl Physiol* **22**, 598–608.
 25. Hounsfield GN (1973) Computerized transverse axial scanning (tomography). 1. Description of system. *Br J Radiol* **46**, 1016–1022.
 26. Al-Gindan YY, Hankey C, Govan L *et al.* (2014) Derivation and validation of simple equations to predict total muscle mass from simple anthropometric and demographic data. *Am J Clin Nutr* **100**, 1041–1051.
 27. Heymsfield SB (1990) Anthropometric measurements: application in hospitalized patients. *Infusionstherapie* **17**, Suppl. 3, 48–51.
 28. Heymsfield SB, McManus C, Smith J *et al.* (1982) Anthropometric measurement of muscle mass: revised equations for calculating bone-free arm muscle area. *Am J Clin Nutr* **36**, 680–690.
 29. Newman AB, Kupelian V, Visser M *et al.* (2006) Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. *J Gerontol A Biol Sci Med Sci* **61**, 72–77.
 30. Goodpaster BH, Park SW, Harris TB *et al.* (2006) The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. *J Gerontol A Biol Sci Med Sci* **61**, 1059–1064.
 31. Chevreul E (1835) Sur la composition chimique du bouillon de viandes (On the chemical composition of meatbroth). *J Pharm Sci Access* **21**, 231–242.
 32. Heymsfield SB, Arteaga C, McManus C *et al.* (1983) Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. *Am J Clin Nutr* **37**, 478–494.
 33. Forbes GB & Bruining GJ (1976) Urinary creatinine excretion and lean body mass. *Am J Clin Nutr* **29**, 1359–1366.
 34. Wang ZM, Sun YG & Heymsfield SB (1996) Urinary creatinine-skeletal muscle mass method: a prediction equation based on computerized axial tomography. *Biomed Environ Sci* **9**, 185–190.
 35. Clark BC & Manini TM (2010) Functional consequences of sarcopenia and dynapenia in the elderly. *Curr Opin Clin Nutr Metab Care* **13**, 271–276.
 36. Patel SS, Molnar MZ, Tayek JA *et al.* (2013) Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. *J Cachexia, Sarcopenia Muscle* **4**, 19–29.
 37. Lukaski HC, Mendez J, Buskirk ER *et al.* (1981) Relationship between endogenous 3-methylhistidine excretion and body composition. *Am J Physiol* **240**, E302–E307.
 38. Dussik KT (1954) The ultrasonic field as a medical tool. *Am J Phys Med* **33**, 5–20.
 39. Ludwig GD, Bolt RH, Heuter TF *et al.* (1950) Factors influencing the use of ultrasound as a diagnostic aid. *Trans Am Neurol Assoc* **51**, 225–228.
 40. Pillen S & van Alfen N (2011) Skeletal muscle ultrasound. *Neurol Res* **33**, 1016–1024.
 41. Smith-Ryan AE, Fultz SN, Melvin MN *et al.* (2014) Reproducibility and validity of A-mode ultrasound for body composition measurement and classification in overweight and obese men and women. *PLoS ONE* **9**, e91750.
 42. Dietz HP (2004) Ultrasound imaging of the pelvic floor. Part II: three-dimensional or volume imaging. *Ultrasound Obstet Gynecol* **23**, 615–625.
 43. Ikai M & Fukunaga T (1968) Calculation of muscle strength per unit cross-sectional area of human muscle by means of ultrasonic measurement. *Int Z Angew Physiol* **26**, 26–32.
 44. Sanada K, Kearns CF, Midorikawa T *et al.* (2006) Prediction and validation of total and regional skeletal muscle mass by ultrasound in Japanese adults. *Eur J Appl Physiol* **96**, 24–31.
 45. Abe T, Loenneke JP, Young KC *et al.* (2015) Validity of ultrasound prediction equations for total and regional muscularity in middle-aged and older men and women. *Ultrasound Med Biol* **41**, 557–564.
 46. Loenneke JP, Thibaud RS & Abe T (2014) Estimating site-specific muscle loss: a valuable tool for early sarcopenia detection? *Rejuvenation Res* **17**, 496–498.
 47. Drakonaki EE, Allen GM & Wilson DJ (2012) Ultrasound elastography for musculoskeletal applications. *Br J Radiol* **85**, 1435–1445.
 48. Harris-Love MO, Monfaredi R, Ismail C *et al.* (2014) Quantitative ultrasound: measurement considerations for the assessment of muscular dystrophy and sarcopenia. *Front Aging Neurosci* **6**, 172.
 49. Pedersen M, Fredberg U, Langberg H *et al.* (2012) Sonoelastography as a diagnostic tool in the assessment of musculoskeletal alterations: a systematic review. *Ultraschall Med* **33**, 441–446.
 50. Watanabe Y, Yamada Y, Fukumoto Y *et al.* (2013) Echo intensity obtained from ultrasonography images reflecting muscle strength in elderly men. *Clin Interv Aging* **8**, 993–998.
 51. Hoffer EC, Meador CK & Simpson DC (1969) Correlation of whole-body impedance with total body water volume. *J Appl Physiol* **27**, 531–534.
 52. Nyboer J (1972) Workable volume and flow concepts of bio-segments by electrical impedance plethysmography. *TIT J Life Sci* **2**, 1–13.
 53. Thomasset A (1962) Bioelectrical properties of tissue impedance measurements. *Lyon Med* **94**, 107–118.
 54. Organ LW, Bradham GB, Gore DT *et al.* (1994) Segmental bioelectrical impedance analysis: theory and application of a new technique. *J Appl Physiol* (1985) **77**, 98–112.
 55. Tan BHL, Birdsell LA, Martin L *et al.* (2009) Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. *Clin Cancer Res* **15**, 6973–6979.
 56. Brown BH, Karatzas T, Nakielnny R *et al.* (1988) Determination of upper arm muscle and fat areas using electrical impedance measurements. *Clin Phys Physiol Meas* **9**, 47–55.

57. Jolene Zheng BZ, Gao C, Watson JM *et al.* (editors) (2014) *Sarcopenic Obesity: Clinical Diagnostic Potential of 8- Electrode Multi-Segmental BIA*. Obesity Week; Boston.
58. Norman K, Stobaus N, Pirlich M *et al.* (2012) Bioelectrical phase angle and impedance vector analysis – clinical relevance and applicability of impedance parameters. *Clin Nutr* **31**, 854–861.
59. Fukumoto Y, Ikezoe T, Yamada Y *et al.* (2012) Skeletal muscle quality assessed from echo intensity is associated with muscle strength of middle-aged and elderly persons. *Eur J Appl Physiol* **112**, 1519–1525.
60. Basile C, Della-Morte D, Cacciatore F *et al.* (2014) Phase angle as bioelectrical marker to identify elderly patients at risk of sarcopenia. *Exp Gerontol* **58**, 43–46.
61. Slee A, Birch D & Stokoe D (2015) Bioelectrical impedance vector analysis, phase-angle assessment and relationship with malnutrition risk in a cohort of frail older hospital patients in the United Kingdom. *Nutrition* **31**, 132–137.
62. Sun Y (2009) Muscle Function Analyzer. China Patent: CN 201370584.
63. Stuart HC & Hill-Dwinell P (1942) The growth of bone, muscle and overlying tissues in children 6 to 10 years of age as revealed by studies of roentgenograms of the leg area. *Monogr Soc Res Child Dev* **13**, 195.
64. Wells PNT (2005) Sir Godfrey Newbold Hounsfield KT CBE. 28 August 1919–12 August 2004: elected F.R.S. 1975. *Biogr Memoirs Fellows R Soc* **51**, 221–235.
65. Bulcke JA, Termote JL, Palmers Y *et al.* (1979) Computed tomography of the human skeletal muscular system. *Neuroradiology* **17**, 127–136.
66. Hagmark T, Jansson E & Svane B (1978) Cross-sectional area of the thigh muscle in man measured by computed tomography. *Scand J Clin Lab Invest* **38**, 355–360.
67. Heymsfield SB, Olafson RP, Kutner MH *et al.* (1979) A radiographic method of quantifying protein-calorie under-nutrition. *Am J Clin Nutr* **32**, 693–702.
68. Tokunaga K, Matsuzawa Y, Ishikawa K *et al.* (1983) A novel technique for the determination of body fat by computed tomography. *Int J Obes* **7**, 437–445.
69. Sjöström S (1984) *Chefer och människor*. 1 uppl ed Solna: SIPU.
70. Macchia RJ, Termine JE, Buchen CD *et al.* (2007) Damadian, M.D.: magnetic resonance imaging and the controversy of the 2003 Nobel Prize in Physiology or Medicine. *J Urol* **178**, 3 Pt 1, 783–785.
71. Mazess RB, Cameron JR & Sorenson JA (1970) Determining body composition by radiation absorption spectrometry. *Nature* **228**, 771–772.
72. Kelly TL, Slovik DM, Schoenfeld DA *et al.* (1988) Quantitative digital radiography versus dual photon absorptiometry of the lumbar spine. *J Clin Endocrinol Metab* **67**, 839–844.
73. Gallagher D, Kuznia P, Heshka S *et al.* (2005) Adipose tissue in muscle: a novel depot similar in size to visceral adipose tissue. *Am J Clin Nutr* **81**, 903–910.
74. Addison O, Marcus RL, Lastayo PC *et al.* (2014) Intermuscular fat: a review of the consequences and causes. *Int J Endocrinol* **2014**, 309570.
75. Heymsfield SB & Noel R (1981) Radiographic analysis of body composition by computerized axial tomography. *Nutr Cancer* **17**, 161–172.
76. Goodpaster BH, Thaete FL, Simoneau JA *et al.* (1997) Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. *Diabetes* **46**, 1579–1585.
77. Prado CM, Maia YL, Ormsbee M *et al.* (2013) Assessment of nutritional status in cancer – the relationship between body composition and pharmacokinetics. *Anticancer Agents Med Chem* **13**, 1197–1203.
78. Heymsfield SB, Smith R, Aulet M *et al.* (1990) Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. *Am J Clin Nutr* **52**, 214–218.
79. Kim J, Wang Z, Heymsfield SB *et al.* (2002) Total-body skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry method. *Am J Clin Nutr* **76**, 378–383.
80. Cruz-Jentoft AJ, Baeyens JP, Bauer JM *et al.* (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. *Age Ageing* **39**, 412–423.
81. Stenholm S, Harris TB, Rantanen T *et al.* (2008) Sarcopenic obesity: definition, cause and consequences. *Curr Opin Clin Nutr Metab Care* **11**, 693–700.
82. Bley TA, Wieben O, Francois CJ *et al.* (2010) Fat and water magnetic resonance imaging. *J Magn Reson Imaging* **31**, 4–18.
83. Karlsson A, Rosander J, Romu T *et al.* (2014) Automatic and quantitative assessment of regional muscle volume by multi-atlas segmentation using whole-body water-fat MRI. *J Magn Reson Imaging* (Epublication ahead of print version).
84. Thomas MS, Newman D, Leinhard OD *et al.* (2014) Test-retest reliability of automated whole body and compartmental muscle volume measurements on a wide bore 3T MR system. *Eur Radiol* **24**, 2279–2291.
85. Quetelet L, Knox R & Smibert T (1842) A treatise on man and the development of his faculties, tr. (under the superintendence of R Knox). [T Smibert, editor]. Edinburgh: William and Robert Chambers.
86. Van Itallie TB, Yang MU, Heymsfield SB *et al.* (1990) Height-normalized indices of the body's fat-free mass and fat mass: potentially useful indicators of nutritional status. *Am J Clin Nutr* **52**, 953–959.
87. Baumgartner RN, Koehler KM, Gallagher D *et al.* (1998) Epidemiology of sarcopenia among the elderly in New Mexico. *Am J Epidemiol* **147**, 755–763.
88. Schuna JM Jr, Peterson CM, Thomas DM *et al.* (2014) Scaling of adult regional body mass and body composition as a whole to height: relevance to body shape and body mass index. *Am J Hum Biol* (Epublication ahead of print version).
89. Siervo M, Prado CM, Mire E *et al.* (2014) Body composition indices of a load-capacity model: gender- and BMI-specific reference curves. *Public Health Nutr*. Available at <http://dx.doi.org/10.1017/S1368980014001918>.
90. Forbes GB (1993) The companionship of lean and fat. *Basic Life Sci* **60**, 1–14.
91. Rolland Y, Gallini A, Cristini C *et al.* (2014) Body-composition predictors of mortality in women aged ≥ 75 y: data from a large population-based cohort study with a 17-y follow-up. *Am J Clin Nutr* **100**, 1352–1360.
92. Cooper R, Kuh D & Hardy R (2010) Objectively measured physical capability levels and mortality: systematic review and meta-analysis. *BMJ* **341**, c4467.
93. Guralnik JM (1997) Assessment of physical performance and disability in older persons. *Muscle Nerve Suppl.* **5**, S14–S16.
94. American College of Sports Medicine (2013) ACSM Guidelines for Exercise Testing and Prescription. 9th edition. London: Lippincott, Williams and Wilkins.
95. Rosenberg IH (1997) Sarcopenia: origins and clinical relevance. *J Nutr* **127**, Suppl. 5, 990S–991S.
96. McLean RR, Shardell MD, Alley DE *et al.* (2014) Criteria for clinically relevant weakness and low lean mass and their

- longitudinal association with incident mobility impairment and mortality: the foundation for the National Institutes of Health (FNIH) sarcopenia project. *J Gerontol A Biol Sci Med Sci* **69**, 576–583.
97. Cawthon PM, Peters KW, Shardell MD *et al.* (2014) Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. *J Gerontol A Biol Sci Med Sci* **69**, 567–575.
 98. Dam TT, Peters KW, Fragala M *et al.* (2014) An evidence-based comparison of operational criteria for the presence of sarcopenia. *J Gerontol A Biol Sci Med Sci* **69**, 584–590.
 99. Lee RC HS, Shen W & Wang ZM (2003) Total-body and regional skeletal muscle mass measurement methods: an overview. *Int J Body Compos Res* **1**, 93–102.
 100. Wang Z, Deurenberg P, Matthews DE *et al.* (1998) Urinary 3-methylhistidine excretion: association with total body skeletal muscle mass by computerized axial tomography. *J Parenter Enteral Nutr* **22**, 82–86.
 101. Janssen I, Heymsfield SB, Baumgartner RN *et al.* (2000) Estimation of skeletal muscle mass by bioelectrical impedance analysis. *J Appl Physiol* (1985) **89**, 465–471.
 102. Kim HK, Lindquist DM, Serai SD *et al.* (2013) Magnetic resonance imaging of pediatric muscular disorders: recent advances and clinical applications. *Radiol Clin North Am* **51**, 721–742.
 103. Robson MD & Bydder GM (2006) Clinical ultrashort echo time imaging of bone and other connective tissues. *NMR Biomed* **19**, 765–780.
 104. Glaser KJ, Manduca A & Ehman RL (2012) Review of MR elastography applications and recent developments. *J Magn Reson Imaging* **36**, 757–774.
 105. Akki A, Yang H, Gupta A *et al.* (2014) Skeletal muscle ATP kinetics are impaired in frail mice. *Age (Dordr)* **36**, 21–30.
 106. Heinicke K, Dimitrov IE, Romain N *et al.* (2014) Reproducibility and absolute quantification of muscle glycogen in patients with glycogen storage disease by ¹³C NMR spectroscopy at 7 Tesla. *PLoS ONE* **9**, e108706.
 107. Zaiss M & Bachert P (2013) Chemical exchange saturation transfer (CEST) and MR Z-spectroscopy *in vivo*: a review of theoretical approaches and methods. *Phys Med Biol* **58**, R221–R269.